Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
Authors
Keywords
Taxane, SNP, Polymorphism, Pharmacogenomics, CYP1B1, ABCB1
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 76, Issue 4, Pages 679-690
Publisher
Springer Nature
Online
2015-07-21
DOI
10.1007/s00280-015-2818-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
- (2014) J. E. Abraham et al. CLINICAL CANCER RESEARCH
- Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations
- (2014) J. Boulanger et al. Current Oncology
- Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach
- (2014) Sonam Tulsyan et al. GENE
- SNPs and taxane toxicity in breast cancer patients
- (2014) Virginia Bosó et al. PHARMACOGENOMICS
- Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
- (2013) Soo-Youn Lee et al. EUROPEAN JOURNAL OF CANCER
- Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy
- (2013) Luis J Leandro-García et al. JOURNAL OF MEDICAL GENETICS
- Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries
- (2013) Zainab Awada et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy
- (2013) Stefanie D Krens et al. PHARMACOGENOMICS
- CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
- (2012) Daniel L. Hertz et al. BREAST CANCER RESEARCH AND TREATMENT
- Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy
- (2012) Kyu-pyo Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel
- (2012) Toshitaka Uchiyama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
- (2012) R. M. Baldwin et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
- (2012) Ningning Dong et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
- (2011) Frederik Marmé et al. BREAST CANCER RESEARCH AND TREATMENT
- Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
- (2011) Theodoros Foukakis et al. BREAST CANCER RESEARCH AND TREATMENT
- Pharmacogenomic Contribution to Drug Response
- (2011) Roshawn G. Watson et al. CANCER JOURNAL
- Impact of CYP3A5*3 and CYP2C8-HapC on Paclitaxel/Carboplatin-Induced Myelosuppression in Patients with Ovarian Cancer
- (2011) Henrik Gréen et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
- (2011) Ranjan Chrisanthar et al. PLoS One
- Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients
- (2010) Roberta Rizzo et al. BREAST CANCER RESEARCH AND TREATMENT
- Pharmacogenomics of paclitaxel
- (2010) Cristina Rodríguez-Antona PHARMACOGENOMICS
- Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
- (2010) S Leskelä et al. PHARMACOGENOMICS JOURNAL
- Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis
- (2009) Theodoros N. Sergentanis et al. BREAST CANCER RESEARCH AND TREATMENT
- Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms
- (2009) Shih-Meng Tsai et al. CLINICA CHIMICA ACTA
- Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study
- (2009) Hee Seung Kim et al. GYNECOLOGIC ONCOLOGY
- Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
- (2009) David R. Gandara et al. JOURNAL OF CLINICAL ONCOLOGY
- Taxane pathway
- (2009) Connie Oshiro et al. Pharmacogenetics and Genomics
- Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
- (2008) H. Chang et al. ANNALS OF ONCOLOGY
- CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
- (2008) V G Martinez et al. BRITISH JOURNAL OF CANCER
- Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor
- (2008) S. Harmsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
- (2008) T. M. Sissung et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic Pathway Analysis of Docetaxel Elimination
- (2008) SD Baker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
- (2008) T. M. Sissung et al. MOLECULAR CANCER THERAPEUTICS
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- (2008) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of paclitaxel resistance in breast cancer: isCYP1B1*3a new factor of influence?
- (2008) Mathias Gehrmann et al. PHARMACOGENOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now